drugset / Trial / NCT01003418
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
Timeline
- Start
- 2009-11-17
- Primary completion
- 2010-11-25
- Completion
- 2010-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2340272A | Vaccine | — | Intramuscular |
| Background | Infanrix™-IPV/Hib | Vaccine | — | Intramuscular |
| Background | Prevnar 13 | Vaccine | — | Intramuscular |